Dr. Joshua Lederberg  
Office of the President  
The Rockefeller University  
1230 York Avenue  
New York, New York 10021

Dear Dr. Lederberg:

In addition to whatever help I can be to you with your clinical research planning, we might discuss the enclosed two papers when we meet on December 1. The first paper describes in abstract form how two vulnerability factors might come together to produce a disorder such as schizophrenia. In this case, low monoamine oxidase activity and being a heterozygote for PKU impact on the formation and metabolism of phenylethylamine.

The second paper deals with the issue of partial brain grafts which may ultimately be of use in treating neurologic disorders. It not only raises many scientific issues but ethical ones as well.

Best wishes and,

Sincerely yours,

R[ichard J. Wyatt, M.D.]
Chief, Laboratory of  
Clinical Psychopharmacology

Enclosure